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Abstract—Diabetes mellitus is a chronic disease causing 
several side effects. The basis of conventional diabetes 
management is the blood glucose detection with 
glucometers. Another approach is the continuous glucose 
monitoring (CGM) that can be the solution for individual 
and optimal management of diabetes because it is less 
painful and inconvenient. Although there are several 
challenges with CGM which must be solved there are proofs 
of the usability and justification of using CGM systems. In 
this paper, we gave a short review of the basics, goals and 
methods of CGM systems. 
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I. INTRODUCTION 
Diabetes mellitus (DM) is a malfunction in the 
regulatory system of human glucose metabolism which is 
connected to the incorrect operation of insulin system. 
[1]. These days, about 347 million people have DM in the 
world [2]. Their number is growing from year by year, 
not just because of the formation of the illness, but also 
due to the better understanding of the disease and because 
of the definition of DM is extending [3]. Due to its 
frightening increase, the World Health Organization 
(WHO) warns that diabetes could be the “disease of the 
future” as diabetic population is predicted to be doubled 
from 2000 to 2030 [4], and according to the WHO’s 
projections, diabetes will be the 7th leading cause of 
death in 2030 [5]. 
The normal blood glucose (BG) level is between 70-
110 mg/dl. Because of this narrow range, the smallest 
error in the control of BG level could lead to the 
dysfunction of the energy household, carbohydrate 
toleration etc. If the untreated condition persists for a 
long time, the side effects of DM (like neuropathy, 
cardiovascular diseases, etc.) make the condition of the 
patient more dangerous [1]. Diabetes is currently 
incurable, but treatable. The mode of treatment depends 
on the type of DM (Type 1 DM (T1DM), Type 2 DM, 
gestational or other) and the condition of the patient (age, 
sex, activity, sicknesses, etc.). From the treatment 
viewpoint, there are two ways: medical or engineering 
option. Despite the fact that the development of medical 
treatments are continuous and there are progress in the 
final cure of diabetes, like pancreatic islet transplantation 
[6-7], better understanding of insulin mechanism [8] or 
experimental drugs to increase the beta cell proliferation 
[9], these methods have increased risk (like immune 
answer, rejection, allergy, etc.) or – because of its 
experimental nature – they are not conclusive solutions 
yet. From engineering point of view, the best solution for 
treating DM is the artificial pancreas (AP). To realize the 
AP, three subunits are needed: (i) an insulin pump (IP), 
which contain the control electronics and the insulin, (ii) 
a continuous glucose monitoring system, which is 
measuring and forwarding the BG or interstitial glucose 
(IG) level and (iii) control algorithms which are realized 
by the insulin pump and accomplish the BG level [10]. 
In conservative therapy, the primary tool for the 
measuring of BG level is the blood glucose meters which 
are widely available in the market. It has several 
advantages and disadvantages, but the main problem is 
that it cannot give continuous data and also the painful 
finger pricking repeatedly a day. 
In contrast to this, continuous glucose monitoring 
(CGM) gives an alternative to conservative BG 
measuring, however it has several drawbacks too, which 
will be reviewed in detail in this study. 
The rest of the paper is organized as follows. First, we 
give an overview of continuous glucose monitoring 
systems. Second, we study the models which are used to 
model the CGMs, then a survey will be given about the 
methods and possibilities in the area of CGMs. Finally, 
we give an overview of the available tools on the market 
and last but not least some concluding remarks. 
II. CONTINUOUS GLUCOSE MONITORING AND ITS 
USAGE 
Continuous glucose monitoring is an essential element 
in the modern DM treatment [10]. As CGMs can be used 
as an individual tool or additional tools, the needed 
subunits can be divided as follows:  
A. if CGM is used in itself then typically the system 
contains three subunits: (i) sensor, which is 
measuring the glucose from blood, interstitial 
fluid (ISF) or else, (ii) data forwarding unit, 
which can be wired or wireless and (iii) data 
processing and displaying unit [11].  
B. if CGM is used with insulin pump, then two 
subunits are needed: (i) sensor, (ii) data 
forwarding unit, which can be wired or wireless 
[10]. 
Tight glycemic control (TGC) is a protocol to keep 
the patient’s glycemic parameters in a narrow range. This 
protocol is widely used in case of diabetes or if the 
patient recovery is better with it [13, 18, 20]. Both A. and 
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B. cases appropriate for TGC realization. CGM used to 
implement TGC protocol could be important especially in 
critically ill patients, childhood diabetes or pregnancy 
[18, 22, 27] although CGM not lived up to expectations 
in pregnancy [23]. 
A. CGM usage as an individual tool 
In those situations when the continuous monitoring of 
BG level is indicated (for example to keep the BG level 
in a given range, or to avoid hypo- or hyperglycemia), but 
there is no need to control the glucose level with insulin, 
the CGM was demonstrated to be a solution. Typically 
these situations include monitoring in intensive care units 
(ICU), patients who are in pre-diabetic stage, in the case 
of chronic alcoholism [12-15]. There are studies which 
showed that the glucose level monitoring in ICU reduced 
the mortality and morbidity [16] and BG level is 
correlated with the recovery after stress (typically after 
surgical intervention) [17]. Significant part of the 
realization is the consensus in CGM protocol usage with 
caregivers [18]. 
B. CGM usage as an additional tool 
The main indication to use insulin pump is when the 
patient has T1DM [19], e.g. there is no internal insulin 
production [1] and has an active lifestyle. Usually in this 
case the CGM system is a subunit of some kind of AP 
system which can be realized with IP. Because the insulin 
pump can handle, display and also process the data, no 
other subunit is needed [20]. 
A recent step forward in CGM use was given by the 
FDA approval of AP from 2012 [21]. 
It is likely that the frontier of CGM will expand due to 
the new challenges (like dual-hormone control), but to 
our knowledge, all available automated BG control 
methods are based only on the blood sugar level. It is 
possible that the CGM method will be supplemented with 
the continuous monitoring of insulin, glucagon or both. 
The fully automated AP is just a future promise now, 
but it can be stated that without CGMs, it is impossible. 
C. Advantages and disadvantages of CGM and a 
comparison with traditional tools 
Although it has clear advantages, the CGM technique 
has disadvantages too. 
Without exception, the available devices are capable 
for BG monitoring, realize real-time CGM (RT-CGM), 
follow the patient records etc. These data and capability 
allows the identification of postprandial hyperglycemia, 
blood glucose variability, hypoglycemia, unexpected 
hypoglycemia, and glucose trends [24]. 
CGM and RT-CGM is beneficial for those who meet 
the following requirements: hypoglycemia unawareness, 
constantly high and/or elevated HbA1c (which is a stable 
form of glycohemoglobin), undue or/and high glucose 
variability, required BG check from fingerstick testing 
more than 10 times a day or dislike this method (which is 
frequent in children's case), rapid rise and fall of BG, 
inability to reach the glycemic goals, need for glycemic 
profile (it is beneficial in professional athletes), and some 
other cases [25]. 
There are various types of CGM sensors and the 
disadvantages of these depend on the applied methods to 
evaluate the BG level. It is generally established that the 
main problems of CGM sensors – independently from the 
measuring methods – are decalibration, inaccuracy, high 
sensitivity to noise and disturbances, possibility of 
infection and/or inflammation (in invasive cases), the 
time delay between the measured glucose level and the 
core glucose level (near liver circulation) [11]. 
The disadvantages are different depending on the 
sensor type. In minimally invasive and implanted sensors 
the infections pose a real threat and patients using 
subcutaneous sensors always need to be aware of it [26-
30].  
An illustration of the benefits and drawbacks of 
CGMs compared with traditional BG meter is given in 
Table I. 
 
III. METHODS TO MEASURE THE BG LEVEL 
A. Summary of the currently used BG detection methods 
There are many detection techniques which are based 
on devices that can measure the BG level directly or 
indirectly. The measuring methods can be divided to 
three types depending on the degree of invasiveness: (i) 
invasive, (ii) minimal invasive, (iii) non-invasive [20]. In 
several cases, there are overlap between the different 
detection methods and used tools. For example, the 
enzymatic type sensors can be applied in invasive and 
non-invasive cases too and depends on what was the 
compartment and/or body-fluid from where the sample 
originated [26]. 
Table II summarizes the sources of measurements and 
grouping by invasiveness. 
Fig.1 presents a classification based on the detection 
method [11, 20]. 
Electrochemical methods 
The glucose detection methods based on 
electrochemical reactions are possible with different 
strategies. It can measure the used oxygen by the 
reactions, the quantity of nascente hydrogen-peroxyd or 
the rate of the electron transfer [32]. The last method can 
be divided into enzymatic or non-enzymatic methods, but 
it is true for all of them that the measured signal is the 
amperometric signal [11]. 
TABLE I.  COMPARISON OF CGMS WITH BG METER 
CGMs Traditional BG meters 
Continuous BG data 
Better TGC realization 
Possible to identify BG trends 
More expensive 
Disturbance, noise sensitiveness 
Bigger time delays 
Sensor needs permanent attention 
More chance to infections 
Calibration required 
Cost effective 
Painful 
Better accuracy 
Smaller time delays 
More chance to inflammation 
Worse TGC realization and BG 
trend identification 
Less BG data 
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The glucose level detection based on enzymatic 
reaction is one of the most common and stable technique 
which can be grouped by the used enzymes [35]. The 
oldest well working method uses the reaction catalized by 
the glucose oxidase (GOx) enzyme (glucose oxidation to 
gluconolactone). The GOx based sensor family can be 
divided into three generations and their reaction products 
are presented in Fig. 2 [31]. These reactions are used by 
most available subcutaneous sensors combined with IP 
[26]. 
Enzymatic, but not GOx based methods are known as 
well [35]; here the principle is similar to GOx based 
methods. Amperometric, but not enzymatic reactions are 
based on the direct redox reaction between the sensor 
material and the local environment (i.e. Ag/Ag+ electrode 
direct e- transfer with extracellular matrix). This direction 
of sensor development is progressing rapidly, because it 
has several advantages against enzymatic methods, like 
accuracy, glucose sensitivity, lower disturbance 
sensitivity (from temperature, local chemical household, 
etc.), lower manufacturing costs etc. [33-34]. 
Optical methods 
There are several optical methods which allow the 
measurement of the quantity of glucose from body fluids 
although not all of that is appropriate to continuous 
glucose monitoring [36]. Fig. 3 summarizes the available 
methods. 
 
Infrared light (IR) based methods work on the idea 
that the change of glucose concentration changes the 
absorption of IR light in the human tissues. The 
difference between these approaches lies in the used 
wavelength. Mid-IR cannot pass through the skin, 
therefore it is used mostly in vitro. In contrast, the Near-
IR (NIR) can be used as in vivo method, because the NIR 
light can penetrate the stratum corneum amongst to the 
subcutaneous tissues [20]. The idea of Thermal-IR 
method is that modulated irradiated energy (a kind of IR 
light) heats the tissue, which increases the temperature 
and the local circulation (the blood vessels expand). 
Hence, the changing of the local glucose level correlates 
with the refractive and reflective coefficients of the 
tissue. Because the circulation becomes more active, the 
level of glucose is increasing. With an indirect way, the 
amount of glucose is detectible from this phenomenon 
[11]. 
Spectroscopy methods (in extended sense, the IR 
based methods belongs here too) are based on the 
changing of the transmitted light during the interaction 
with the substrate. Raman spectroscopy uses the inelastic 
Raman-scattering of monochromatic light which depends 
on the energy states of molecules (rotational, vibrational, 
or other). When the incident monochromatic light interact 
with the substrate, different lines appear in the spectrum 
 
Figure 3.  Optical based glucose measuring methods 
 
Figure 2.  Amperometric glucose detection method with 
enzymatic reaction [31] 
TABLE II.  THE MOST COMMON METHODS TO MEASURING 
GLUCOSE LEVEL 
Body fluids 
Measuring options 
Invasive Minimal invasive Non-invasive 
Blood 
Intravenous 
catheter; 
implant 
BG meter (via 
finger pricking) 
Optical based 
devices; Other 
Interstitial 
fluid Implant 
Subcutaneous 
sensor 
Not usual, but 
possible 
Urine - - In vitro analyzers 
Eyewater - - 
In vitro 
analyzers; 
Surface 
electrode (in 
contact lens) 
 
 
 
Figure 1.  Detection technologies (GOx – Glucose-Oxidase 
enzyme) [11, 20] 
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which are symmetric, but weaker than the original light. 
Here it is needed to investigate the Raman-effect of the 
glucose molecules when they interact with the used light. 
Because every molecule has different image in the 
spectrum, this method is suitable for distinguish the 
different molecules too [11]. Occlusion spectroscopy uses 
the pulsatile arterial blood flow. It is suitable solution for 
measuring the general state (quantity and quality) of 
blood because it can measure the property of blood 
particles, like red blood cells (RBC). Investigating the 
scatter pattern of RBC aggregation at the site the glucose 
concentration can be evaluated [40]. The principle of 
scattering spectroscopy is the same as occlusion 
spectroscopy. The scattering (from refraction and 
reflection) of tissues depend on the particles which 
procreate the tissue. The quantity of the glucose in the 
tissue (solid material or body fluids) correlates with the 
scattering properties of the tissue; hence, the glucose 
amount becomes measurable [20]. 
The optoacoustic (or photoacoustic) method can be 
classified as spectroscopy methods although the 
measured signal is basically different from the other 
spectroscopy methods. The point of this approach is 
based on the focused irradiated light absorbing in the 
tissues which causes local heating. Due to the increasing 
temperature, the tissue suffers thermal expansion. This 
expansion generates an ultrasound pulse which can be 
measured. As the concentration of glucose is correlated 
with the thermal properties of the tissue, the glucose 
concentration can be evaluated [42]. 
Optical coherence tomography (OCT) is based on the 
low coherence interferometry. The reason why this 
method is suitable for glucose detection is the fact that 
the OCT is very sensitive for the changing refractivity of 
the sample. The presence of glucose molecules affects the 
refractive indices of the tissue; thus, the amount of 
glucose is measurable by indirect way. Chromoscopy 
principle is the same as OCT, but it is based on the 
transmitted and scattering light [11]. 
Polarimetry based methods use linearly polarized 
light passed through on the optically active sample and 
rotating the light plane of polarization. Only the 
asymmetric molecules have the ability of optical rotation 
so this is a limitation of this method. The rotation of light 
depends on several factors, including the glucose 
concentration of the sample [20]. 
Fluorescence based methods are not so many, but they 
are different based on the source of fluorescence. The 
point of this phenomenon is the light emission by an 
optically active material after the irradiation of light was 
ended. One of the first approaches used the dextran 
labeled by fluorescein as the source of the emission. In 
this case, the receptor is the concanavalin A (conA) 
protein to which the glucose and dextran can bind (these 
two molecules are competitive agonists here). The 
emitted light is increasing when the dextran is not 
connected to conA. Another approach is the using the 
fluorescence resonance energy transfer (FRET) to 
measure the glucose concentration. The essence of this 
method is the energy transfer between to fluorophore 
molecule if they are closer than the Förster-radius (the 
maximum distance while the energy transport exists). 
These two are the basic methods, but further ones can be 
found in the literature [20, 39]. 
There are other methods to measure the BG level. 
One of these approaches is the microwave based method 
[37]. Another technic is based on radio frequency [38]. 
Other methods 
There is no consensus about the classification of the 
following methods what are presented from the literature. 
Sonophoresis utilizes that low-ultrasound increases 
the permeability of skin what makes easier to add drugs 
or measuring glucose through the stratum corneum [41]. 
Reverse iontophoresis uses electrical current with low 
intensity between two electrodes on the surface of the 
skin causing the changing of the local chemical 
household because of the ions flow to the electrodes. The 
consequence is that small amount of fluids from 
interstitial space leak out the pores that is enough to 
measure with another method (like GOx based) [44]. Skin 
blister suction utilizes the power of vacuum to create an 
inside fluid vesicle near the surface of the skin whereon 
the ISF are collecting. Then this fluid can be analyzed, 
externally [47]. 
Microporation utilizes focused, low powered laser 
beam to create micropores on the skin through the ISF 
that can be collected by vacuum or pressure. From this 
fluid, the glucose concentration can be detected [47]. The 
last four methods are collectively known as Transdermal 
Methods (TM) [11]. 
Microdyalisis uses ex-vivo sensor to analyze the 
blood or ISF glucose concentration. It is based on the 
conventional dyalisis techniques [20]. Impedance 
spectroscopy uses alternating current which is traverse 
through the tissues and this current can be detected. 
Because the local concentration of glucose changes the 
electric properties of tissues the amount of glucose is 
measurable [45]. Electromagnetic glucose detection is 
based on the phenomena that the electromagnetic 
permittivity of the tissue is influenced by the local 
glucose concentration. The presence of glucose is well 
visible in the electromagnetic spectrum [46]. Microneedle 
arrays are good alternative because they are less painful 
and minimal invasive. The microneedles on the carrier 
surface create microtunnels. Through these ISF and blood 
can be collected but also drugs (like insulin) can be 
delivered. To our knowledge, this technique is not used as 
lab-on-a-chip approach yet [48]. 
Several disturbances interfere with the detection of 
glucose quantity. The fact is that every method has 
weaknesses which can distort the measurements as it 
clear from the referred literature. Broadly speaking, the 
main disturbance sources are the following: molecules 
with the same optical, electrical, physiological and other 
physical properties like the glucose, the physical 
properties of the investigated tissues, environmental 
effects (like temperature, light contamination, electric and 
magnetic field, etc.). 
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B. The used body materials to detect the glucose level 
Several body fluids and samples are proper to 
establish the glucose level of the body. Naturally the most 
relevant is blood through the glucose transport to the 
large part of the cells. Almost every mentioned method is 
suitable for that. The oldest indicator of DM is the urine. 
In DM, the amount of sugar is increasing because of the 
higher glucose secretion of the kidneys. The testing of 
urine for glucose is the part of standard laboratory test 
nowadays [51]. 
Other approach is the glucose detection from saliva 
possible for example by enzymatic way. This method is 
appropriate to differentiate the healthy and DM persons 
[52]. 
Glucose detection from eyewater is another 
possibility as well. Detection with wearable contact lens 
with enzymatic detection is a suitable painless solution 
[53]. Moreover, BG level can be evaluated from 
breathing too. However, this process is able to detect only 
high glucose level [49]. 
C. Equality of data from different methods 
Because of the difference between the glucose 
measuring methods the gathered data are different. 
Comparing the measured BG level with different devices 
(based on different methods) making the measurements 
accurate and comparable the Continuous (Clarke type) 
and Consensus (Parke type) Error Grid methods [50] are 
used. 
IV. GOALS OF IN-SILICO MODELLING 
In these days the using of in-silico simulation and 
modelling in medical field is not questionable. The CGM 
modelling is a proper important field inside the DM 
modelling. The accuracy of simulation of human systems 
is eligible only if every subpart of the whole model is 
eligible. There are several challenging tasks in this field 
and there are no adequate solutions for these yet. The 
most important two of these are the following: 
• The dynamics of the patients are similar, but 
different from many aspects: depends on the 
signals (food, increasing glucose BG level, brain 
commands through the nervous system, etc.), 
actuators (hormones, dynamics of intestine 
system, etc.), time-lag (from different 
compartments because of absorption, diffusion, 
active transport, etc.) and other aspects [1, 20].  
• The structure and identification of CGM models 
mostly depends on the methods of the glucose 
measuring and data processing applied [54-57]. 
V. SUMMARY 
Lot of methods are available to detect the amount of 
glucose from human samples and several methods are 
appropriate to realize continuous glucose monitoring. The 
devices available on the market are using the mentioned 
methods to realize the CGM systems often in a combined 
way (than multi-sensors), but there are several problems 
which must be solved to further development (accuracy, 
data equality from different methods, modelling 
questions, etc.). The CGM approaches are involving 
continuously and the trends show that the CGM system is 
expected to become more integrated to the AP concept 
[58]. 
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